Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation

Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation

Ponatinib is a multi-targeted third generation tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukemia (CML) patients harboring the Abelson (Abl)-breakpoint cluster region (Bcr) T315I mutation. In spite of having superb clinical efficacy, ponatinib triggers severe vascular...

Full description

Bibliographic Details
Main Authors: Jesus Paez-Mayorga, Andrew L. Chen, Sivareddy Kotla, Yunting Tao, Rei J. Abe, Emma D. He, Brian P. Danysh, Marie-Claude C. Hofmann, Nhat-Tu Le
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
ponatinib
vascular adverse events
ERK5 SUMOylation
EC inflammation
tyrosine kinase inhibtor (TKI)
Online Access:https://www.frontiersin.org/article/10.3389/fcvm.2018.00125/full

Internet

https://www.frontiersin.org/article/10.3389/fcvm.2018.00125/full

Similar Items